Prior to co-founding Enliven, Sam was an Executive Director of Research at AbbVie and the Head of Research at AbbVie Stemcentrx. Sam started at Stemcentrx as Senior Director, Strategy and Business Development.
Sam has also served as Vice President, Business Development and Applications, at Biodesy, a South San Francisco–based biotech startup developing and commercializing novel protein conformation technology for small molecule drug discovery.
Additionally, Sam has worked at Roche Venture Fund, where he triaged and sourced investment opportunities in the life sciences industry. He has also worked as a medicinal chemist at Genentech, where he designed and synthesized small molecule drugs for the treatment of cancer and neurodegenerative diseases.
Sam received both an MBA and a Bachelor of Science in Chemistry, with Honors, from Stanford University.